SynOx Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $75.0Mattributed |
|---|---|
| Latest round | series-b, $75.0M, 2024-04-01attributed |
| Founded | 2020 |
| Headquarters | Dublin Ireland |
| Industry | biotech|oncology|therapeutics |
| Stage | series-b+ |
| Website | synoxtherapeutics.com |
SynOx Therapeutics is developing emactuzumab, a monoclonal antibody against CSF-1R, to shut down macrophage-driven disease activity. It targets patients with tenosynovial giant cell tumor and other macrophage-driven rare diseases where treatment options are thin. Focusing all R&D on one antibody builds deeper macrophage-biology expertise than a broad pipeline allows.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | series-b | $75.0M | undisclosed |
Detected tech stack
Cloudflare, reCAPTCHA, Slick 1.8.1, jQuery CDN, jQuery Migrate 3.4.1, PHP, cdnjs, Contact Form 7 6.1.6, Cookiebot, Vercel Speed Insights, Onsen UI, WordPress
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $75.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $75.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | synoxtherapeutics.com, read 2026-05-07 |
| Description | self-reported | synoxtherapeutics.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.